1. TAMI-34. TARGETING CSF1R AND PD1 IN EXPERIMENTAL GLIOMA
- Author
-
Marilin Koch, Anja Pohl, Martina Schmittnaegel, Hannes Becker, Anna-Lena Keller, Nataliya Korinetska, Ghazaleh Tabatabai, Nicole Anderle, Jens Schittenhelm, Marcos Tatagiba, Justyna Przystal, Foteini Tsiami, Christian Schmees, Carola Ries, Denis Canjuga, and Susanne C. Beck
- Subjects
Macrophage colony-stimulating factor ,Cancer Research ,Tumor microenvironment ,biology ,Chemistry ,Tumor-associated macrophage ,26th Annual Meeting & Education Day of the Society for Neuro-Oncology ,Fibrinogen ,medicine.disease ,Oncology ,Glioma ,Cancer research ,medicine ,biology.protein ,Neurology (clinical) ,Antibody ,Cytotoxicity ,medicine.drug ,Glioblastoma - Abstract
The treatment of glioblastoma remains a challenge. Novel therapeutic strategies are urgently needed. Targeting the immunosuppressive glioblastoma-associated microenvironment is an interesting approach in this regard. Tumor-associated macrophages represent a distinct population of tumor-infiltrating immune cells with tumor-promoting features. The colony stimulating factor-1/ colony stimulating factor-1 receptor (CSF-1/CSF1R) axis plays an important role for macrophage differentiation and survival inside the tumor microenvironment. We thus aimed at investigating the antiglioma activity of CSF1R inhibition alone or in combination with blockade of programmed death (PD) 1. We detected CSF1R expression in paired tissue samples of primary and corresponding progressive glioblastoma. We investigated anti-CSF1R treatment alone or in combination with anti-PD1 antibodies in the orthotopic syngeneic VM/Dk SMA560 glioma mouse model, evaluated post-treatment effects and assessed treatment-induced cytotoxicity in a coculture model of patient-derived microtumors (PDM) and autologous tumor-infiltrating lymphocytes (TILs) ex vivo. Anti-CSF1R monotherapy increased the latency until the onset of neurological symptoms. Combinations of anti-CSF1R and anti-PD1 antibodies prolonged the latency until the onset of neurological symptoms and led to long-term survivors in vivo. Immunohistochemical analysis of post-treatment SMA-560 glioma revealed a modulation of the microenvironment, including increased T cell infiltration and reduced numbers of tumor-associated macrophages. Furthermore, we observed treatment-induced cytotoxicity of combined anti-CSF1R and anti-PD1 treatment in the PDM/TILs cocultures ex vivo. Taken together, our data indicates that CSF1R is a promising therapeutic target for glioblastoma, potentially in combination with PD1 inhibition.
- Published
- 2021